FineCell has completed a new investment round in Jul 2026, strengthened the company’s financial position and brought new investors into its ownership base. The investment comes at an important stage in FineCell’s development. Following the launch of RheoTouch®, the company’s first commercial product for the personal care market. FineCell is seeing increasing interest from customers and partners internationally after being launched recently in Paris, New York, and Seoul:
https://www.linkedin.com/feed/update/urn:li:activity:7478703369650483200
The new investment will support the company’s continued commercial development, customer evaluations, and preparations for scaling up production capacity.
Existing shareholders also took part in the round, proving continued confidence in FineCell’s technology and commercial potential. In addition, new investors with experience from business development, entrepreneurship and technology have joined the company.
“We are very pleased to see both existing and new investors supporting FineCell at this stage,” says Peter Axegård, Chairman of the Board of FineCell. “The market response to RheoTouch® and the growing interest in our cellulose fibril technology give us an increasingly strong platform for the next phase of the company’s development.”
The company is continuing its discussions with potential investors and strategic partners as FineCell prepares for the next stage of growth and scale-up.